GlassScriptPhysician profile
Jeffrey Michaelson
NPI 1063495521
$22,001.29
in general payments reported to CMS, 2019-2025
40 companies · $568 in 2025
The $568 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,925 · 2020: $999 · 2021: $3,485 · 2022: $4,175 · 2023: $8,454 · 2024: $2,396 · 2025: $568.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,425 · Food and Beverage: $3,854 · Education: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,425.00 |
| Food and Beverage | $3,854.29 |
| Education | $138.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $13,385.11 | 2019-2024 | Ofev |
| United Therapeutics Corporation | $1,873.97 | 2019-2025 | Tyvaso, Tyvaso |
| Harmony Biosciences LLC | $1,203.50 | 2020-2024 | Wakix |
| Jazz Pharmaceuticals INC. | $774.40 | 2019-2024 | |
| Glaxosmithkline, LLC. | $689.72 | 2019-2024 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $656.74 | 2019-2024 | Tezspire, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $488.35 | 2019-2024 | |
| Insmed, INC. | $473.39 | 2019-2025 | Arikayce, Brinsupri |
| Genzyme Corporation | $294.85 | 2019-2024 | |
| Actelion Pharmaceuticals US, INC. | $286.28 | 2019-2024 | Uptravi, Opsumit |
| Merck Sharp & Dohme LLC | $197.85 | 2019-2024 | Winrevair |
| Janssen Research & Development, LLC | $189.24 | 2019 | |
| Mallinckrodt Enterprises LLC | $173.43 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $130.95 | 2022-2023 | Dupixent |
| Baxter Healthcare | $91.97 | 2023-2024 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $89.80 | 2023-2024 | Purified Cortrophin Gel |
| Grifols USA, LLC | $87.95 | 2023-2024 | Prolastin-C Liquid, Xembify |
| Philips North America LLC | $76.30 | 2019-2023 | |
| Mylan Specialty L.P. | $72.28 | 2019-2023 | Yupelri |
| Pfizer INC. | $66.60 | 2020-2022 | |
| Axsome Therapeutics, INC. | $63.50 | 2022-2023 | Sunosi |
| Sanofi-Aventis U.S. LLC | $61.99 | 2023 | |
| Amgen INC. | $60.50 | 2023 | Tezspire |
| Inspire Medical Systems, INC. | $51.21 | 2024 | Inspire |
| Takeda Pharmaceuticals U.S.A., INC. | $43.83 | 2022-2023 | Glassia |
| E.R. Squibb & Sons, L.L.C. | $43.81 | 2019-2025 | Camzyos |
| Tactile Systems Technology INC | $41.99 | 2023-2024 | Flexitouch Plus, Entre Plus |
| Mallinckrodt Hospital Products INC. | $41.83 | 2021 | |
| Advanced Respiratory, INC | $39.26 | 2020-2021 | |
| Pulmonx Corporation | $36.22 | 2023-2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Genentech USA, INC. | $34.75 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $30.64 | 2022 | |
| Phadia US INC. | $28.17 | 2019 | |
| Nabriva Therapeutics, Plc | $27.42 | 2020 | |
| Gilead Sciences, INC. | $21.88 | 2019 | |
| Zoll Respicardia, INC. | $18.11 | 2025 | Remede System |
| Ethicon US, LLC | $14.53 | 2022 | |
| Sandoz INC. | $14.21 | 2021 | |
| Circassia INC. | $13.51 | 2019 | |
| Novo Nordisk INC | $11.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Michaelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.